AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Frequently asked questions
What sector does AbCellera Biologics Inc (ABCL) operate in?
AbCellera Biologics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is AbCellera Biologics Inc (ABCL) current stock price?
As of the latest data, AbCellera Biologics Inc stock price is $12.08, with a previous close of $11.82. AbCellera Biologics Inc gained $0.26 in the last trading session, representing a 2.2% increase.
What is AbCellera Biologics Inc (ABCL) current market capitalization?
AbCellera Biologics Inc market cap is approximately 3.91 billion.
What is AbCellera Biologics Inc (ABCL) Earnings Per Share (EPS)?
The trailing EPS is -$0.54, and the forward EPS is -$0.78.
What is AbCellera Biologics Inc (ABCL) EBITDA?
AbCellera Biologics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -50.18 million.
Does AbCellera Biologics Inc (ABCL) pay dividends?
No. AbCellera Biologics Inc does not pay a dividend.
How did AbCellera Biologics Inc (ABCL) perform in its most recent earnings report?
In the last report (June 30, 2026), AbCellera Biologics Inc posted an EPS surprise of -5.88% and a revenue surprise of -49.17%.
When is AbCellera Biologics Inc (ABCL) next earnings report?
AbCellera Biologics Inc is expected to release its next earnings report on September 30, 2026.
What is AbCellera Biologics Inc (ABCL) beta (volatility) score?
AbCellera Biologics Inc has a beta of 1.410, suggesting it is more volatile than the market.
